Faculty

Institution

Unit

Venue

Thomas Lodise

Albany College of Pharmacy and Health Sciences

Affiliations

Research Institute For Health Outcomes

Thomas Lodise is a Senior Professor at the Albany College of Pharmacy and Health Sciences. His research focuses on infectious diseases, clinical microbiology, and antimicrobial pharmacology, with specific interests in antimicrobial resistance, healthcare-associated infections, and antimicrobial stewardship. His latest work includes DOOR analyses of isavuconazole versus voriconazole for invasive mold disease, hollow fiber infection model studies of imipenem/relebactam against Pseudomonas aeruginosa, and assessments of the BioFire FilmArray Pneumonia Panel in the VA healthcare system. He has also published on dalbavancin for Staphylococcus aureus bacteremia in JAMA and the clinical burden of carbapenem-resistant Acinetobacter baumannii. His research integrates pharmacodynamic modeling, diagnostic stewardship, and health-economic outcomes to optimize treatment strategies for resistant bacterial and fungal infections.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Thomas Lodise

Albany College of Pharmacy and Health Sciences

You can click a keyword to filter the displayed items

medicine infectious diseases clinical microbiology infection control antibiotics hospital infections antimicrobial resistance pharmacology antimicrobial agents antimicrobial stewardship healthcare-associated infections clinical epidemiology antimicrobial chemotherapy drug resistance respiratory medicine pharmacotherapy epidemiology antibiotic resistance antimicrobial susceptibility pathogenic bacteria veterinary medicine clinical infection hospital epidemiology hospital medicine applied pharmacology pharmacokinetics clinical research intensive care applied microbiology emerging infectious diseases klebsiella pneumoniae medical microbiology clinical pharmacology clinical infectious disease medicinal research dermatological treatment acute bacterial skin skin structure infections hospitalized patients adult patients antibacterial agents respiratory infections drug safety antibiotic adjuvant medical mycology disease transmission health systems acute kidney injury systematic review community-acquired bacterial pneumonia pharmacological research diagnostic microbiology clinical therapeutics pharmacoepidemiology dialysis therapy therapeutic drug monitoring serious infections blood purification antimicrobial resistance genes clinical mycology clinical effectiveness intensive care unit preventive medicine infectious respiratory disease clinical dermatology infectious disease modelling bacteriology community-acquired pneumonia mrsa bloodstream infections outpatient setting economic impact treatment and prevention vancomycin exposure clinical outcomes monte carlo simulation vancomycin area

Notable Scholarly Works

Notable Federal Grants

Collaborators

147. Clinical Impact of the Biofire® Filmarray® Pneumonia (Pn) Panel in the Veteran Affairs Healthcare System Using a Difference-In-Difference (Did) Design. Open Forum Infectious Diseases (2026)

outcomes researchhealth careclinical effectivenessmedicineinternal medicinecritical carehospital infectionshealthcare-associated infectionsclinical impactbiofire® filmarray® pneumoniahealth services researchclinical laboratory

P-1249. Effect of Starting Inoculum and β-Lactamase Retention on the Activity of Imipenem/Relebactam (I/R) and Aztreonam (Atm) Plus I/R in Hollow Fiber Infection (Hfim) Studies of P. Aeruginosa (Psa). Open Forum Infectious Diseases (2026)

pathogenic bacteriaantimicrobial agentsp. aeruginosabiofilmsinfection controlmicrobiologystarting inoculuminfectious diseasesclinical microbiologyantimicrobial chemotherapyantibacterial agentsapplied microbiologyantimicrobial resistancebiochemistryhollow fiber infectionantimicrobial susceptibilityantibiotics

P-1960. Desirability of Outcome Ranking (Door) Analysis of Isavuconazole Relative to Voriconazole for the Treatment of Invasive Mold Disease (Imd). Open Forum Infectious Diseases (2026)

outcome rankingmedical mycologymedicineisavuconazole relativeinfectious diseasesantifungal agentsantimicrobial resistanceclinical mycologyinvasive mold diseasefungus

P-786. Comparison of Length of Stay and Hospitalization Costs Among Patients With Complicated Urinary Tract Infection Including Acute Pyelonephritis by Antibiotic Hospital Discharge Treatment Strategy. Open Forum Infectious Diseases (2026)

urologyinfection controlmedicinehospital infectionshealthcare-associated infectionshospitalization costsacute pyelonephritisantimicrobial stewardshiphealth services researchantibiotics

Safety and Efficacy of Fecal Microbiota, Live-Jslm for Prevention of Recurrent Clostridioides Difficile Infection Among Hospitalized Participants in Punch Cd3-Ols. Infectious Diseases and Therapy (2026)

pathogenic bacteriapathogensinfection controlmicrobiologyinfectious diseaseshospital infectionshealthcare-associated infectionsmicrobiomedysbiosisgut microbesmicrobial diseasepunch cd3-olsfecal microbiotahospitalized participantsclinical microbiology

Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals. Clinical Infectious Diseases (2025)

hospital medicineoutcomes researchmedicineassociation between durationhealth carehealthcare-associated infectionsintensive careclinical epidemiologyhealth services researchemergency medicinemedical mycologycandidemia whoempiric treatmentinternal medicinehospital epidemiologyhospital infectionsclinical managementhealth systemsclinical mycology

Clinical Burden of Acinetobacter Baumannii, Including Carbapenem-Resistant a. Baumannii, in Hospitalized Adult Patients in the USA Between 2018 and 2022. BMC Infectious Diseases (2025)

antibioticsantimicrobial agentsmedicinehospital epidemiologyinfectious diseaseshospital infectionsdrug resistanceclinical microbiologyhospitalized adult patientsclinical burdenantimicrobial resistanceantibiotic resistanceantimicrobial stewardshipacinetobacter baumanniiepidemiology

Comparison of Early Treatment With Ceftolozane/Tazobactam Versus Polymyxin-Based Therapy of Pneumonia Due to Mdr Pseudomonas Aeruginosa (Puma). Antimicrobial Agents and Chemotherapy (2025)

lung microbiomeantimicrobial agentsmedicineinfectious diseaseshospital infectionsclinical microbiologyantibacterial agentsantimicrobial chemotherapyantimicrobial resistanceearly treatmentantimicrobial stewardshipklebsiella pneumoniaeantibiotic adjuvantantibiotics

Dalbavancin for Treatment of Staphylococcus Aureus Bacteremia. JAMA (2025)

pathogenic bacteriaantimicrobial agentsinfection controlmedicineinfectious diseasesclinical microbiologyantimicrobial chemotherapyantimicrobial resistanceantibiotic adjuvantantimicrobial stewardshipantibiotics

P-1092. Re-Analysis of Pivmecillinam Randomized Clinical Trial Data According to 2019 Us Food and Drug Administration Guidance for the Treatment of Uncomplicated Urinary Tract Infection. Open Forum Infectious Diseases (2025)

urologyantimicrobial agentsinfection controlmedicineinfectious diseaseshospital infectionsinfectious diseases (medical specialty)clinical epidemiologyus foodantimicrobial stewardshipurological researchdrug administration guidanceantibiotics

1
2
3
4
5
33
10 / page

Thomas Lodise

Albany College of Pharmacy and Health Sciences

Affiliations

Research Institute For Health Outcomes

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Thomas Lodise

Albany College of Pharmacy and Health Sciences

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

147. Clinical Impact of the Biofire® Filmarray® Pneumonia (Pn) Panel in the Veteran Affairs Healthcare System Using a Difference-In-Difference (Did) Design. Open Forum Infectious Diseases (2026)

P-1960. Desirability of Outcome Ranking (Door) Analysis of Isavuconazole Relative to Voriconazole for the Treatment of Invasive Mold Disease (Imd). Open Forum Infectious Diseases (2026)

outcome rankingmedical mycologymedicineisavuconazole relativeinfectious diseasesantifungal agentsantimicrobial resistanceclinical mycologyinvasive mold diseasefungus

urologyinfection controlmedicinehospital infectionshealthcare-associated infectionshospitalization costsacute pyelonephritisantimicrobial stewardshiphealth services researchantibiotics

Clinical Burden of Acinetobacter Baumannii, Including Carbapenem-Resistant a. Baumannii, in Hospitalized Adult Patients in the USA Between 2018 and 2022. BMC Infectious Diseases (2025)

Comparison of Early Treatment With Ceftolozane/Tazobactam Versus Polymyxin-Based Therapy of Pneumonia Due to Mdr Pseudomonas Aeruginosa (Puma). Antimicrobial Agents and Chemotherapy (2025)

Dalbavancin for Treatment of Staphylococcus Aureus Bacteremia. JAMA (2025)

1
2
3
4
5
33
10 / page